AssetMark Inc
BBIO icon

AssetMark Inc’s BridgeBio Pharma BBIO Stock Holding History

AssetMark Inc’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.79M Buy
24,056
+3,266
+16% +$229K ﹤0.01% 979
2026
Q1 		$1.54M Buy
20,790
+16,820
+424% +$1.22M ﹤0.01% 940
2025
Q4 		$304K Sell
3,970
-448
-10% -$29.4K ﹤0.01% 1223
2025
Q3 		$229K Buy
4,418
+1,608
+57% +$78.4K ﹤0.01% 1240
2025
Q2 		$121K Sell
2,810
-52
-2% -$1.89K ﹤0.01% 1326
2025
Q1 		$98.9K Sell
2,862
-112
-4% -$3.78K ﹤0.01% 1283
2024
Q4 		$81.6K Sell
2,974
-444
-13% -$11.5K ﹤0.01% 1293
2024
Q3 		$87K Buy
3,418
+156
+5% +$4.09K ﹤0.01% 1172
2024
Q2 		$82.6K Buy
3,262
+433
+15% +$11.8K ﹤0.01% 1137
2024
Q1 		$87.5K Sell
2,829
-102
-3% -$3.47K ﹤0.01% 1067
2023
Q4 		$118K Buy
2,931
+935
+47% +$28.1K ﹤0.01% 1009
2023
Q3 		$52.6K Buy
+1,996
New +$56.6K ﹤0.01% 1088

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

AssetMark Inc's BBIO Position: Q2 2026 in Review

AssetMark Inc increased its BridgeBio Pharma (BBIO) stake by 16% in Q2 2026, buying an estimated $229K and bringing the position to 24,056 shares worth $1.79M. The position accounts for ﹤0.01% of the portfolio, ranked #979.

AssetMark Inc first reported a position in BBIO in Q3 2023 and has held it in 12 quarters since. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • AssetMark Inc held 24,056 shares of BridgeBio Pharma worth $1.79M as of Q2 2026.
  • AssetMark Inc bought 3,266 BridgeBio Pharma shares in Q2 2026, an estimated $229K.
  • BridgeBio Pharma made up ﹤0.01% of AssetMark Inc's portfolio in Q2 2026, its #979 holding.
  • AssetMark Inc first reported a position in BridgeBio Pharma in Q3 2023 and has held it in 12 quarters since.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on AssetMark Inc's 13F filing for Q2 2026, filed 30 Jul 2026.